Information Provided By:
Fly News Breaks for August 10, 2015
MNKD
Aug 10, 2015 | 15:16 EDT
Piper Jaffray analyst Joshua Schimmer said in a post-earnings note on MannKind that he stills has concerns about the company's financial position and the trajectory for Afrezza, adding that he believes the company may need to re-evaluate its strategy if there is not an inflection of prescriptions for the inhaled insulin in the coming months. Schimmer maintains a Neutral rating on MannKind shares but raised his price target on the stock to $4 from $3.50 to reflect the lower spending evident in its Q2 report.
News For MNKD From the Last 2 Days
There are no results for your query MNKD
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.